Atrioventricular Block and Cluster Headache

Who is this study for? Patients with cluster headache
What treatments are being studied? Verapamil
Status: Active_not_recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

Verapamil is a calcium channel blocker widely used to treat cardiovascular diseases however it is also the first line treatment in the prevention of cluster headaches. In France, its prescription in that indication is based on compliance with the Temporary Recommendation for Use (RTU) that insists on the possible the cardiac side effects that can occur as the doses required for cluster headache are significantly higher than the doses used in cardiology.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• patient 18 years old, and older

• patient suffering from Cluster Headache (according to the l'ICHD-3 diagnostic criterias)

• patients affiliated to the social security

• patient that has given his full written consent to participate in the study

• female patients participating in the study must be using an efficient contraception for more than 1 month prior to the beginning of the study

Locations
Other Locations
France
AP-HP Hôpital la Timone
Marseille
CHU de Nice
Nice
Time Frame
Start Date: 2020-11-02
Completion Date: 2027-09-05
Participants
Target number of participants: 60
Treatments
Other: Verapamil
administration of verapamil to treat cluster headache
Related Therapeutic Areas
Sponsors
Leads: Centre Hospitalier Universitaire de Nice

This content was sourced from clinicaltrials.gov